GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Mangoceuticals Inc (NAS:MGRX) » Definitions » ROE %

Mangoceuticals (Mangoceuticals) ROE % : 0.00% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mangoceuticals ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Mangoceuticals's annualized net income for the quarter that ended in Mar. 2024 was $-9.47 Mil. Mangoceuticals's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $-0.09 Mil. Therefore, Mangoceuticals's annualized ROE % for the quarter that ended in Mar. 2024 was N/A%.

The historical rank and industry rank for Mangoceuticals's ROE % or its related term are showing as below:

MGRX' s ROE % Range Over the Past 10 Years
Min: -1326.42   Med: -997.89   Max: -564.11
Current: -564.11

During the past 3 years, Mangoceuticals's highest ROE % was -564.11%. The lowest was -1,326.42%. And the median was -997.89%.

MGRX's ROE % is ranked worse than
97.87% of 610 companies
in the Healthcare Providers & Services industry
Industry Median: 4.395 vs MGRX: -564.11

Mangoceuticals ROE % Historical Data

The historical data trend for Mangoceuticals's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mangoceuticals ROE % Chart

Mangoceuticals Annual Data
Trend Dec21 Dec22 Dec23
ROE %
- -669.35 -1,326.42

Mangoceuticals Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only -462.17 -267.84 -330.24 -964.51 -

Competitive Comparison of Mangoceuticals's ROE %

For the Health Information Services subindustry, Mangoceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mangoceuticals's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Mangoceuticals's ROE % distribution charts can be found below:

* The bar in red indicates where Mangoceuticals's ROE % falls into.



Mangoceuticals ROE % Calculation

Mangoceuticals's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-9.212/( (0.614+0.775)/ 2 )
=-9.212/0.6945
=-1,326.42 %

Mangoceuticals's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-9.472/( (0.775+-0.958)/ 2 )
=-9.472/-0.0915
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Mangoceuticals  (NAS:MGRX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-9.472/-0.0915
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-9.472 / 0.856)*(0.856 / 0.676)*(0.676 / -0.0915)
=Net Margin %*Asset Turnover*Equity Multiplier
=-1106.54 %*1.2663*N/A
=ROA %*Equity Multiplier
=-1401.21 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-9.472/-0.0915
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-9.472 / -9.472) * (-9.472 / -9.472) * (-9.472 / 0.856) * (0.856 / 0.676) * (0.676 / -0.0915)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1 * -1106.54 % * 1.2663 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Mangoceuticals ROE % Related Terms

Thank you for viewing the detailed overview of Mangoceuticals's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mangoceuticals (Mangoceuticals) Business Description

Traded in Other Exchanges
N/A
Address
15110 N. Dallas Parkway, Suite 600, Dallas, TX, USA, 75248
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provide access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED product.
Executives
Amanda Elizabeth Hammer officer: Chief Operating Officer 5128 GADSDEN AVENUE, KELLER TX 76244
Jacob D. Cohen director, 10 percent owner, officer: CEO 2101 GLENDALE DRIVE, PLANO TX 75023
Tiger Cub Trust 10 percent owner 19 RYDDINGTON PL, DALLAS TX 75230
Kenny Myers director 5101 ADDISON CIRCLE,, UNIT 401,, ADDISON TX 75001
Lorraine Pamela D'alessio director 8200 WILSHIRE BLVD, BEVERLY HILLS, CALIFORNIA CA 90211
Eugene M Johnston officer: CFO PO BOX 669047, CHARLOTTE NC 28266
Jonathan Arango director, officer: President, COO and Secretary 15110 DALLAS PARKWAY, SUITE 600, DALLAS TX 75248
Alex P. Hamilton director 26 LOOP ROAD, BEDFORD NY 10506